STT3A-AS1: A Potential Drug Target and Biomarker (G105369550)

Target Name: STT3A-AS1

NCBI ID: G105369550

STT3A-AS1

Other Name(s): STT3A antisense RNA 1

STT3A-AS1: A Potential Drug Target and Biomarker

Stimulus-triggered calcineurin (STT3A) is a protein that plays a critical role in cell signaling pathways, including intracellular signaling, DNA damage repair, and neurotransmission. STT3A has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. The STT3A gene has been implicated in the development of various diseases, including cancer.

Recent studies have identified STT3A as a potential drug target and biomarker for various diseases, including cancer (4, 5). The potential drug targets for STT3A include the regulation of cell adhesion, the inhibition of STT3A-mediated neurotransmission, and the inhibition of STT3A-mediated signaling pathways (6, 7).

Potential Drug Targets

1.Regulation of Cell Adhesion

STT3A has been shown to be involved in cell adhesion, and its regulation of cell adhesion has been identified as a potential drug target. Cell adhesion is a critical process that enables cells to maintain their structural integrity, communicate with other cells, and participate in various signaling pathways. The regulation of cell adhesion is critical for the development and progression of various diseases, including cancer.

2.Inhibition of STT3A-mediated Neurotransmission

STT3A has been shown to be involved in neurotransmission, and its regulation of neurotransmission has been identified as a potential drug target. Neurotransmission is the process by which brain cells communicate with each other and the rest of the body, and it is critical for the development and progression of various diseases, including depression, anxiety, and neurodegenerative diseases. The regulation of neurotransmission is critical for the development and progression of these diseases, and targeting STT3A in this pathway may be a potential drug target.

3.Inhibition of STT3A-mediated Signaling Pathways

STT3A has been shown to be involved in various signaling pathways, including TGF-β signaling pathway, PI3K/Akt signaling pathway, and NF-kappa-B signaling pathway (14, 15). These signaling pathways are critical for the development and progression of various diseases, including cancer. The inhibition of STT3A-mediated signaling pathways may be a potential drug target.

Biomarker

STT3A has been shown to be involved in various cellular processes, including cell adhesion, neurotransmission, and signaling pathways. Its regulation of cell adhesion, neurotransmission, and signaling pathways may be potential drug targets for various diseases, including cancer (18, 19). The potential drug targets for STT3A have been identified based on its involvement in various cellular processes, and further studies are needed to determine its effectiveness as a biomarker and potential drug target.

Conclusion

STT3A has been shown to be involved in various cellular processes, including cell adhesion, neurotransmission, and signaling pathways. Its regulation of cell adhesion, neurotransmission, and signaling pathways may be potential drug targets for various diseases, including cancer. Further studies are needed to determine the effectiveness of STT3A as a biomarker and potential drug target.

Protein Name: STT3A Antisense RNA 1

The "STT3A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STT3A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets